New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 24, 2012
07:45 EDTAEGRAegerion announces Boxed Warning for newly-FDA approved Juxtapid
Juxtapid contains a Boxed Warning citing the risk of hepatic toxicity. The safety and effectiveness of Juxtapid have not been established in patients with hypercholesterolemia, or HoFH, who do not have HoFH. The effect of Juxtapid on cardiovascular morbidity and mortality has not been determined. The safety and effectiveness of Juxtapid have not been established in pediatric patients. The FDA based its approval of Juxtapid on Aegerion's pivotal Phase III study, which evaluated the safety and effectiveness of the medicine to reduce LDL-C levels in 29 adult patients with HoFH. In this study, Juxtapid was initiated at 5 mg daily and gradually escalated to doses of 10 mg, 20 mg, 40 mg, up to 60 mg, based on tolerability and acceptable liver enzymes levels. The most common adverse reactions in the Phase III trial were gastrointestinal. Adverse reactions included diarrhea, nausea, vomiting, dyspepsia and abdominal pain. Other common adverse reactions included weight loss, abdominal discomfort, abdominal distension, constipation, flatulence, increased ALT, chest pain, influenza, nasopharyngitis, and fatigue. Elevations in liver enzymes and hepatic fat were also observed.
News For AEGR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
09:59 EDTAEGROn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Aegerion (AEGR) downgraded to Underperform from Neutral at BofA/Merrill... Archer Daniels (ADM) downgraded to Hold from Buy at Argus... Bed Bath & Beyond (BBBY) downgraded to Perform from Outperform at Oppenheimer... Best Buy (BBY) downgraded to Perform from Outperform at Oppenheimer... Boeing (BA) downgraded to Neutral from Overweight at JPMorgan... CSX (CSX) downgraded to Market Perform from Outperform at Avondale... Comstock Resources (CRK) downgraded to Neutral from Buy at Ladenburg... EV Energy (EVEP) downgraded to Neutral from Buy at Ladenburg... FNFV (FNFV) downgraded to Market Perform from Outperform at Keefe Bruyette... Flowers Foods (FLO) downgraded to Hold from Buy at Deutsche Bank... Goldcorp (GG) downgraded to Sector Performer from Outperformer at CIBC... Group 1 Automotive (GPI) downgraded to Sector Weight from Overweight at KeyBanc... HSBC cuts Sprint (S) to sell, says competitors may make turnaround difficult... KAR Auction (KAR) downgraded to Neutral from Buy at Goldman... LINN Energy (LINE) downgraded to Sell from Neutral at Citi... LPL Financial (LPLA) downgraded to Market Perform from Outperform at Wells Fargo... Legacy Reserves (LGCY) downgraded to Neutral from Buy at Ladenburg... LinnCo (LNCO) downgraded to Sell from Neutral at Citi... Memorial Production (MEMP) downgraded to Neutral from Buy at Ladenburg... NetApp (NTAP) downgraded to Underweight from Neutral at Atlantic Equities... Netflix (NFLX) downgraded to Market Perform from Outperform at FBR Capital... Nu Skin (NUS) downgraded to Neutral from Buy at Sidoti... Oceaneering (OII) downgraded on multiple headwinds at RBC Capital... Och-Ziff Capital (OZM) downgraded to Neutral from Buy at Compass Point... Stone Energy (SGY) downgraded to Neutral from Buy at Ladenburg... Vanguard Natural (VNR) downgraded to Neutral from Buy at Ladenburg.
08:34 EDTAEGRAegerion downgraded to Underperform on share loss at BofA/Merrill
As previously reported, BofA/Merrill downgraded Aegerion to Underperform. Analyst Tazeen Ahmad said Aegerion's sales force reduction will result in a longer time for the company to regain patient share loss and reduced his price target on shares to $6 from $13.
06:49 EDTAEGRAegerion downgraded to Underperform from Neutral at BofA/Merrill
February 11, 2016
07:03 EDTAEGRAegerion announces 25% reduction in global workforce
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use